REFERENCES

• BerkM,DeanO,DrexhageH,et al.Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness.BMC Med.2013117423324495
   PubMed Web of Science ®Google Scholar
• MendlewiczJ,KriwinP,OswaldP,Souery D,AlboniS,BrunelloN.Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study.Int Clin Psychopharmacol.2006214227231
   Web of Science ®Google Scholar
• SavitzJ,PreskornS,TeagueTK,DrevetsD,YatesW,DrevetsW.Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trial.BMJ Open.201221e000643https://doi.org/10.1136/bmjopen-2011-000643.
   PubMed Web of Science ®Google Scholar
• RosenblatJD,KakarR,BerkM,et al.Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis.Bipolar Disord.20161828910126990051
   PubMed Web of Science ®Google Scholar
• KöhlerO,BenrosME,NordentoftM,et al.Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. 71JAMA Psychiatry.2014 121381139125322082
   PubMed Web of Science ®Google Scholar
• HusainMI,StrawbridgeR,StokesPR,YoungAH.Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis.J Psychopharmacol.201731911371148
   Web of Science ®Google Scholar
• LaanW,GrobbeeDE,SeltenJP,HeijnenCJ,KahnRS,BurgerH.Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial.J Clin Psychiatry.2010715520527
   Web of Science ®Google Scholar
• DeardorffWJ,GrossbergGT.Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics.Exp Rev Neurother.20171711732
   Web of Science ®Google Scholar
• Nevado-HolgadoAJ,LovestoneS.Determining the molecular pathways underlying the protective effect of non-steroidal anti-inflammatory drugs for Alzheimer’s disease: A bioinformatics approach.Comput Struct Biotechnol J.2017151727872687
   PubMed Web of Science ®Google Scholar
• LemonnierE,VilleneuveN,SonieS,et al.Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders.Transl Psychiatry.201773e1056https://doi.org/10.1038/tp.2017.10. 28291262
   PubMed Web of Science ®Google Scholar
• LemonnierE,LazartiguesA,Ben-AriY.Treating schizophrenia with the diuretic bumetanide: a case report.Clin Neuropharmacol.201639211511726966887
   PubMed Web of Science ®Google Scholar
• RahmanzadehR,ShahbaziA,ArdakaniMK,MehrabiS,RahmanzadeR,JoghateaeiMT.Lack of the effect of bumetanide, a selective NKCC1 inhibitor, in patients with schizophrenia: a double-blind randomized trial.Psychiatry Clin Neurosci.2017711727327800670
   PubMed Web of Science ®Google Scholar
• LowryJA,BrownJT.Significance of the imidazoline receptors in toxicology.Clin Toxicol (Phila).2014 Jun5254546924666288
   PubMed Web of Science ®Google Scholar
• Attention deficit hyperactivity disorder : diagnosis and management. Available at :
   Google Scholar
• NaguyA.Clonidine use in psychiatry: panacea or panache.Pharmacology.2016981-2879227161101
   PubMed Web of Science ®Google Scholar
• FioreMC,JaénCR,BakerTB,et al.Treating tobacco use and dependence: 2008 update.Clinical Practice Guideline.2008
   Google Scholar
• KungS,EspinelZ,LapidMI.Treatment of nightmares with prazosin: a systematic review.Mayo Clin Proc.201287989090022883741
   PubMed Web of Science ®Google Scholar
• BerlinRK,ButlerPM,PerloffMD.Gabapentin therapy in psychiatric disorders: a systematic review.Prim Care Companion CNS Disord.201517510.4088/PCC.15r01821https://doi.org/10.4088/PCC.15r01821.
   Google Scholar
• CulpepperL,WingertzahnMA.Over-the-counter agents for the treatment of occasional disturbed sleep or transient insomnia: a systematic review of efficacy and safety.Prim Care Companion CNS Disord.201517610.4088PCC.15r01798https://doi.org/10.4088/PCC.15r01798
   Google Scholar
• GuaianaG,BarbuiC,CiprianiA.Hydroxyzine for generalised anxiety disorder.Cochrane Database Syst Rev.201012CD006815https://doi.org/10.1002/14651858.CD006815.pub2
   Google Scholar
• IadarolaND,NiciuMJ,RichardsEM,et al.Ketamine and other N-methyl-D-aspartate receptor antoagnonists in the treatment of depression: a perspective review.Ther Adv Chronic Dis.2015639711425954495
   PubMed Web of Science ®Google Scholar
• FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. Available at:
   Google Scholar
• KishiT,MatsunagaS,OyaK,NomuraI,IkutaT,IwataN.Memantine for Alzheimer’s disease: an updated systematic review and meta-analysis.J Alzheimers Dis.201760240142528922160
   PubMed Web of Science ®Google Scholar
• Garido-MesaN,ZarzueloA,GalvezJ.Minocycline: far beyond an antibiotic.Br J Pharmacol.2013169233735223441623
   PubMed Web of Science ®Google Scholar
• RosenblatJD,McIntyreRS.Efficacy and tolerability of minocycline for depression: a systematic review and meta-analysis of clinical trials.J Affect Disord.201822721922529102836
   PubMed Web of Science ®Google Scholar
• SavitzJB,TeagueTK,MisakiM,et al.Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial.Transl Psychiatry.20188127https://doi.org/10.1038/s41398-017-0073-7. 29362444
   PubMedGoogle Scholar
• MurroughJW,HurykKM,MaoX,et al.A pilot study of minocycline for the treatment of bipolar depression: effects on cortical glutathione and oxidative stress in vivo.J Affect Disord.201812305664
   Google Scholar
• DeakingB,SucklingJ,BarnesTRE,et al.The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomized, double-blind, placebo-controlled trial.Lancet Psychiatry.201851188589430322824
   PubMed Web of Science ®Google Scholar
• LevkovitzY,MendlovichS,RiwkesS,et al.A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia.J Clin Psychiatry.201071213814819895780
   PubMed Web of Science ®Google Scholar
• XiangYQ,ZhengW,WangSB,et al.Adjunctive minocycline for schizophrenia: a meta-analysis of randomized controlled trials.Eur Neuropsychopharmacol.201727181827919523
   PubMed Web of Science ®Google Scholar
• UmedaT,OnoK,SakaiA,et al.Rifampicin is a candidate preventive medicine against amyloid-beta and tau oligomers.Brain.20161391568158627020329
   PubMed Web of Science ®Google Scholar
• YulugB,HanogluL,OzansovM,et al.Therapeutic role of rifampicin in Alzheimer’s disease.Psychiatry Clin Neurosci.201872315215929315976
   PubMed Web of Science ®Google Scholar
• LoebMB,MolloyDW,SmiejaM,et al.A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer’s disease.J Am Geriatr Soc.20045238138714962152
   PubMed Web of Science ®Google Scholar
• IizukaT,MorimotoK,SasakiY,et al.Preventive effect of rifampicin on Alzheimer disease needs at least 450 mg daily for 1 year: an FDG-PET follow-up study.Dement Geriatr Cogn Dis Extra.20177201214
   Web of Science ®Google Scholar
• MolloyDW,StandishTI,ZhouQ,GuyattG,DARAD Study group.A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer’s disease: The DARAD trial.Int J Geriatr Psychiatry.20132846347022718435
   PubMed Web of Science ®Google Scholar
• LizukaT,MorimotoK,SasakiY,et al.Preventive effect of rifampicin on Alzheimer disease needs at least 450 mg daily for 1 year: an FDG –PET follow-up study.Dement Geriatr Cogn Dis Extra.20177220421428690634
   PubMed Web of Science ®Google Scholar
• PetersonTC,BrownIR.Cysteamine in combination with N-acetylcysteine prevents acetaminophen-induced hepatotoxicity.Can J Physiol Pharmacol.19927012081581851
   PubMed Web of Science ®Google Scholar
• MinariniA,FerrariS,GalletiM,et al.N-acetylcysteine in the treatment of psychiatric disorders: current status and future prospects.Expert Opin Drug Metab Toxicol.201713327929227766914
   PubMed Web of Science ®Google Scholar
• Deepmala,J,SlatteryJ,KumarN,et al.Clinical trials of N-acetylcysteine in psychiatry and neurology: a systematic review.Neurosci Biobehav Rev.20155529432125957927
   PubMed Web of Science ®Google Scholar
• ZhenW,ZhangQE,CaiDB,et al.N-acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials.Acta Psychiatr Scand.2018137539140029457216
   PubMed Web of Science ®Google Scholar
• SharmaA,GerbargP,BottiglieriT,et al.S-Adenosylmethionine (SAMe) for neuropsychiatric disorders: a clinician-oriented review of research.J Clin Psychiatry. 2017786e656e66728682528
   PubMed Web of Science ®Google Scholar
• ShawK,TurnerJ,Del MarC.Tryptophan and 5-hydroxytryptophan for depression.Cochrane Database Syst Rev.2002 1CD00319811869656
   PubMedGoogle Scholar
• HoriH,KunugiH.Dopamine agonist-
responsive depression.Psychogeriatrics.20161338995
   Google Scholar
• CorriganMH,DenahanAQ,WrightCE,RagualRJ,EvansDL.Comparison of pramipexole, fluoxetine, and placebo in patients with major depression.Depress Anxiety.2000112586510812530
   PubMed Web of Science ®Google Scholar
• YathamLN,KennedySH,ParikhSV,SchafferA,BondDJ,FreyBN.Canadian Network for mood and anxiety treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.Bipolar Disord.20182029717029536616
   PubMed Web of Science ®Google Scholar
• ShinguK,KawaiI,YamadaK.Thee cases of unipolar delusional depression responsive to L-dopa.Folia Psychiatr Neurol Jpn.1979334511515535833
   PubMedGoogle Scholar
• KoellaWP.CNS-related (side-)effects of beta blockers with special reference to mechanisms of action.Eur J Clin Pharmacol.198528Suppl55632865151
   PubMedGoogle Scholar
• CruickshankJM.The clinical importance of cardioselectivity and lipophilicity in beta blockers.Am Heart J.19801001601786105819
   PubMed Web of Science ®Google Scholar
• RavarisCL,FriedmanMJ,HauriPJ,McHugoGJ.A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients.J Clin Psychopharmacol.19911163443501770152
   PubMed Web of Science ®Google Scholar
• SteenenSA,van WijkAJ,van der Heijden GJ,van WestrhenenR,de LangeG,de JonghA.Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis.J Psychopharmacol.201630212813926487439
   PubMed Web of Science ®Google Scholar
• LonerganMH,Olivera-FigueroaLA,PitmanRK,BrunetA.Propranolol’s effects on the consolidation and reconsolidation of long-term emotional memory in healthy participants: a meta-analysis.J Psychiatry Neurosci.2013334222231
   Google Scholar
• BurbielJC.Primary prevention of posttraumatic stress disorder: drugs and implications.Mil Med Res.2015224https://doi.org/10.1186/s40779-015-0053-2. 26504586
   PubMedGoogle Scholar
• BrunetA,OrrSP,TremblayH,Robertson K,NaderK,PitmanRK.Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driver traumatic imagery in post-traumatic stress disorder.J Psychiatr Res.200842650350617588604
   PubMed Web of Science ®Google Scholar
• BrunetA,SaumerD,LiaA,StreinerDl,TremblayJ,PitmanRK.Reduction of PTSD symptoms with pre-reactivation propranolol therapy : a randomized controlled trial.Am J Psychiatry.2018175542743329325446
   PubMed Web of Science ®Google Scholar
• ShenH,LiR,YanR,et al.Adjunctive therapy with statins in schizophrenia patients : a meta-analysis and implications.Psychiatry Res.2018262849329427912
   PubMed Web of Science ®Google Scholar
• HayesJF,lundiA,WicksS,et al.Association of hydroxylmethyl glutaryl coenzymes A reductase inhibitors, L-type calcium channel antagonists, and biguanides with rates of psychiatric hospitalization and self-harm in individuals with serious mental illness.JAMA Psychiatry. 201976438239030624557
   PubMed Web of Science ®Google Scholar
• El-HageW,LemanS,CamusV,BelzungC.Mechanisms of antidepressant resistance.Front Pharmacol.2013414624319431
   PubMed Web of Science ®Google Scholar
• KennedySH,LamRW,McIntyreRS,et al.Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3.Pharmacological Treatments. Can J Psychiatry.201661954056027486148
   PubMed Web of Science ®Google Scholar
• ToumaKTB,ZouchaAM,ScarffJR.Liothyronine for depression: a review and guidance for safety monitoring.Innov Clin Neurosci.2017143-42429
   PubMedGoogle Scholar
• ParmentierT,SienaertP.The use of triiodothyronine (T3) in the treatment of bipolar depression: A review of the literature.J Affect Disord.201822941041429331701
   PubMed Web of Science ®Google Scholar
• SchafferA,McIntoshD,GoldsteinBI,et al.The canadian network for mood and anxiety reatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders.Ann Clin Psychiatry.201224162222303519
   PubMed Web of Science ®Google Scholar
• KatzmanMA,BleauP,BlierP,et al.Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.BMC Psychiatry.201414Suppl 1S125081580
   PubMed Web of Science ®Google Scholar
• YildizA,NikodemM,VietaE,CorrellCU,BaldessariniRJ.A network meta- analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania.Psychol Med.20154529931725036226
   PubMed Web of Science ®Google Scholar
• Anti-inflammatoires non stéroïdiens (AINS) et complications infectieuses graves – Point d’information. Available at:
   Google Scholar
• MassoudF,GauthierS.Update on the pharmacological treatment of Alzheimer’s disease.Curr Neuropharmacol.201081698020808547
   PubMed Web of Science ®Google Scholar
• QiW,GevondenM,ShalyA.Preventionof post-traumatic stress disorder after trauma : current evidence and future directions.Curr Psychiatry Rep.2016182026797860
   PubMed Web of Science ®Google Scholar
• SijbrandijM,KleiboerA,BissonJI,BarbuiC,CuijpersP.Pharmacological prevention of post-traumatic stress disorder and acute stress disorder: a systematic review and meta-analysis.Lancet Psychiatry.20152541342126360285
   PubMed Web of Science ®Google Scholar
• BaldwinDS,AndersonIM,NuttDJ,et al.Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.J Psychopharmacol.201428540334924713617
   PubMed Web of Science ®Google Scholar
• De la TorreJC.Cerebral perfusion enhancing interventions: a new strategy for the prevention of Alzheimer Dementia.Brain Pathol.201626561863127324946
   PubMed Web of Science ®Google Scholar
• De la TorreJC.Carotid artery ultrasound and echocardiography testing to lower the prevalence of Alzheimer’s disease.J Stroke Cerebreovasc Dis.200918431928
   PubMed Web of Science ®Google Scholar
• CocaA,MonteagudoE,ComénechM,CamafortM,SierraC.Can the treatment of hypertension in the middle-aged prevent dementia in the elderly?High Blood Press Cardiovasc Prev.20162329710427075454
   PubMedGoogle Scholar
• ElamoshyR,BirdY,ThorpeL,MorarosJ.Risk of depression and suicidality among diabetic patients: a systematic review and meta-analysis.J Clin Med.2018711445https://doi.org/10.3390/jcm7110445.
   PubMed Web of Science ®Google Scholar
• HarrigerJA,ThompsonJK.Psychological consequences of obesity: weigh bias and body image in overweight and obese youth.Int Rev Psychiatry.201224324725322724646
   PubMed Web of Science ®Google Scholar
• RajanTM,MenonV.Psychiatric disorders and obesity: a review of association studies.J Postgrad Med.201763318219028695871
   PubMed Web of Science ®Google Scholar